May 18th 2024
A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
Kathy Oubre: Other Players Complicate Biosimilar Use for Cancer Centers
July 2nd 2020Kathy Oubre, chief operating officer at the Pontchartrain Cancer Center in Louisiana, president of the Louisiana Medical Group Management Association and member of the board of directors for the Community Oncology Alliance, discusses how payers, pharmacy benefit managers, and manufacturers make providing biosimilars complicated for patients and providers.
Rheumatologists Still Leery of Biosimilar Use, Study Says
June 30th 2020In surveys conducted in February and March 2020, rheumatologists cited low adoption rates of biosimilars by payers and unfavorable discounts as major reasons why they feel uncomfortable switching prescribing patterns from reference products to biosimilars.
Doctors Manage Insulin Degludec-to-Glargine Transition Poorly, ADA Study Says
June 20th 2020There is much inconsistency in the way physicians transition patients from insulin degludec to insulin glargine upon hospital admission, leading to higher risk especially for patients with type 1 diabetes, according to a study presented at the American Diabetes Association 80th Scientific Sessions online conference.
Rising Costs Explain Why Canada Is Switching to Biosimilars
June 15th 2020Following in the footsteps of British Columbia, other Canadian provinces are working to implement their own biosimilars initiatives that would switch patients from some of the most costly reference biologics to biosimilar counterparts.
Part 1: NCCN Panel Discusses Patient Education on Biosimilars
May 22nd 2020Patient preferences play a large role in the effort to get biosimilars into the mainstream of therapeutics, and education is often a struggle, panelists said at the National Comprehensive Cancer Network (NCCN) 2020 Virtual Annual Conference.
ISPOR Panelists Weigh the Success of APMs
May 19th 2020The alternative payment model (APM) doesn’t perfectly balance the competing interests of revenue growth and value-based care, but it has been a learning tool, panelists said at Virtual ISPOR 2020, the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research.
Panelists Advocate for Global Collaboration in RWE Effort
May 19th 2020Harmonized efforts across global borders and among stakeholders are needed to generate and build acceptance of real world evidence (RWE) to actively aid in health care decision making, panelists said at Virtual ISPOR 2020, the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research.